Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Pipette and test tubes

Through the collaboration, Oxford academics will work with Janssen scientists to develop a cellular map of genes and proteins implicated across a range of immune-mediated inflammatory disorders and characterize pharmacologically relevant therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation.

Lead Oxford investigator for the project, Professor Holm Uhlig said, 'This exciting endeavor brings together a world leading group of Janssen and Oxford scientists to form the Cartography collaboration. This project aims to create a detailed cellular map across multiple immune disorders which has the potential to advance the understanding of disease mechanisms, how to treat the right patients with the right medications, and the development of new therapies.'

Read the full story on the University of Oxford website.

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Professor Susan Jebb appointed as Chair of the Food Standards Agency

Susan Jebb, Professor of Diet and Population Health in Oxford University’s Nuffield Department of Primary Care Health Sciences, has been appointed as the new Chair of the Food Standards Agency.